Ki-67 expression as a diagnostic biomarker in odontogenic cysts and tumors: A systematic review and meta-analysis

Mahnaz Jabbarzadeh1, Michael R. Hamblin2, Fatemeh Pournaghi-Azar1, Maedeh Vakili Saatloo1, Maryam Kouhsoltani1, Nafiseh Vahed5

1Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran
2Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa
3Department of Restorative Dentistry, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran
4Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Urmia University of Medical Sciences, Urmia, Iran
5Research Center for Evidence-based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract
Ki-67 is a marker of cell proliferation, used as an important diagnostic marker in the pathologic differentiation of various lesions. It is also relevant for developing targeted molecular therapies. We carried out a systematic review to assess the Ki-67 labeling index (LI) in odontogenic cysts and tumors. Databases were searched, including PubMed (MEDLINE), Scopus, CINHAL, PsycoInfo, the Cochrane Library, and Proquest. The meta-analysis was carried out based on the data of 608 lesions. When a 5% cut-off point was set, ki-67 LI of all benign odontogenic tumors dropped below this point. All the malignant tumors demonstrated an LI of over 15.3%; a significantly higher Ki-67 LI in malignant odontogenic lesions (17.59 ± 2.80) was observed. Among benign tumors, the largest and the smallest Ki-67 LIs were seen in ameloblastoma (4.39 ± 0.47) and adenomatoid odontogenic tumor (0.91 ± 1.71). The mean values of Ki-67 LI in tumors and cysts were 4.23 (0.38) and 1.04 (0.07), respectively. Among odontogenic cysts, the highest Ki-67 LI was found in odontogenic keratocyst (OKC) (3.58 ± 0.51), and the lowest in the radicular cyst (1.29 ± 0.62%). Ki-67 LIs in all odontogenic cysts were <3%, except for OKC. This controversial lesion seems to have a profile more similar to a tumor, and a treatment plan similar to tumors might be suggested. We found that odontogenic lesions have diverse proliferative activities that help differentiate between various lesions and suggest therapeutic plans.

Introduction
Odontogenic lesions are one of the most common pathologic entities in the jaw region. Odontogenic cysts arise from different types of odontogenic epithelial cell types. The most common odontogenic cyst is the dentigerous cyst, which accounts for 20% of all the mandibular epithelial cysts.1 An odontogenic keratocyst (OKC) is classified as a dental lamina cyst with a tendency to relapse after surgery, and it exhibits relatively aggressive clinical behavior. OKCs have a different origin, progression course, and biological behavior from other odontogenic cysts, e.g., dentigerous or radicular cysts.2 Relatively high mitotic activity and increased epithelial cell turnover rates have been proposed to account for the growth of OKCs.3 In 2005, OKC was classified as a benign odontogenic tumor in the WHO classification; however, it is still debated whether OKC is a benign tumor or an odontogenic cyst.4 Ameloblastoma, the most prevalent clinically significant odontogenic tumor, comprises 1% of all jaw cysts or tumors, and 10–45.2% of all odontogenic tumors. Ameloblastoma is a benign tumor with a tendency for local invasion and a high recurrence rate; it is divided into solid/multicystic, unicystic, and peripheral subtypes.5 Unicystic ameloblastoma displays a lining of focal or fully ameloblastic epithelium upon histopathological examination.6 Ameloblastic carcinoma is a malignant epithelial odontogenic tumor that might develop within an existing ameloblastoma.7,8 Abnormal cell proliferation is an essential feature of tumorigenesis. Ki-67 is a 319–358 kDa protein, considered a reliable marker for the proportion of proliferating cells and to predict the lesion’s behavior.9,10 Ki-67 is involved in all the active stages of the cell cycle (G1, S, G2, and M phases), but is not present in the resting G0 phase.11 The

ARTICLE INFO
Article History:
Received: 28 June 2020
Accepted: 30 Aug. 2020
ePublished: 13 Feb. 2021

Keywords:
Biomarker
Ki-67 labeling index
Odontogenic cysts
Odontogenic tumor

© 2021 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
most common standard for evaluating the tumor for Ki-67 expression is to calculate the percentage of positive nuclear staining with an anti-Ki-67 antibody, which is described as the Ki-67 labeling index (LI).\textsuperscript{12} Ki-67 expression has been used in the diagnosis of many different human tumors, e.g., breast cancer, meningioma, prostate cancer, non-Hodgkin lymphoma, soft tissue sarcoma, etc.\textsuperscript{15}

Ki-67 is a diagnostic molecular marker involved in the growth of cancer cells. It is often assayed during the histopathological examination and has also been used for developing therapeutic methods.\textsuperscript{14} In the maxillofacial region, Ki-67 has been used for distinguishing between adenoid cystic carcinoma (ACC) and polymorphous low-grade adenocarcinoma (PLGA), two histopathologically similar lesions, but with different biological behavior and clinical outcome. Based on previous studies, the mean Ki-67 LI for PLGA and ACC has been reported to be 1.24% and 3.71%, respectively.\textsuperscript{15} The Ki-67 LI has also been used to distinguish between two other lesions, basal cell adenocarcinoma (BCAC) and basal cell adenoema. The mean Ki-67 LI values in BCAC and BCA were 4.4% and 2.1%, respectively. The authors suggested a Ki-67 LI cut-off point of 5% and observed that 91% of BCAC LI values were higher than this cut-off point. Accordingly, a high Ki67 LI value could be helpful in BCAC diagnosis.\textsuperscript{16}

Ki-67 is a diagnostic and prognostic marker based on many statistical and laboratory findings and is, therefore, a promising candidate to differentiate between various lesions and suggest the best treatment approach.\textsuperscript{14} This study aimed to systematically review the role of Ki-67 LI in odontogenic cysts and tumors. To the best of our knowledge, this is the first review assessing Ki-67 LI in odontogenic lesions.

**Materials and Methods**

This systematic review was carried out based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines for reporting systematic reviews.

**Search strategies**

PubMed (MEDLINE), Scopus, CINHAL, PsycoInfo, the Cochrane Library, and Proquest were used as the search databases. The key words were selected based on Medical Subject Heading (MeSH) terms. The studies were retrieved by searching for the following keywords: “odontogenesis”, “odontogenic cyst”, “keratocyst”, “odontogenic keratocyst”, “radicular cyst”, “ki67”, “malignant ameloblastoma”, “ameloblastic sarcoma”, “ameloblastic fibrosarcoma”, “odontogenic carcinoma”, “odontogenic malignancy”, “CEOT”, “KCOT”, “MIB-1 antigen”, “MIB-1 protein”, “antigen MIB 1”, “protein MIB 1”, “Ki67 antigen”, “dentigerous cyst”, “radicular cyst”, “follicular cyst”, “periapical cyst”, “calcifying odontogenic cyst”, “residual cyst”, “glandular odontogenic cyst”, “dental tissue neoplasm”, “odontogenic tumor”, “odontogenic tumor”, “odontogenic adenomatoid tumor”, “odontogenic adenomatoid tumor”, “odontogenic neoplasm”, “odontogenic cancer”, “odontoma”, “ondontome”, “squamous odontogenic tumor”, “meloblastic sarcoma”, “ameloblastic fibrosarcoma”, “odontogenic sarcoma”, “malignant odontogenic tumor”, “benign odontogenic myxoma”, “ameloblastic fibroma”, “squamous odontogenic tumour” and “calcifying epithelial odontogenic tumor” from 1990 to 2019 (August).

**Study selection and eligibility criteria**

The inclusion criteria were as follows:

1. Studies on the Ki-67 expression levels in odontogenic cysts and tumors published from 1990 to 2019 (August).
2. Articles published in the English language with full-text availability.
3. Ki-67 values expressed as a percentage or LI evaluated by counting (the number of positive cells/total number of cells) \times 100
4. Ki-67 LI reported as mean ± SD

The following studies were excluded: non-human research, reviews, letters, editorials, expert opinions, articles written in a language other than English, studies that reported ranges instead of means ± SD, studies in which the value was not expressed as a percentage, articles of poor quality, studies that did not include qualitative staining and immunohistochemistry analysis, duplicated articles (risk of bias).

**Quality assessment**

Using the CASP (Critical Appraisal Skills Program) quality checklist, the included articles were independently assessed by two specialists in oral and maxillofacial pathology (M.K. and M.V.), and low-quality studies were excluded.

**Data extraction**

Two investigators (M.K. and M.J.) independently extracted the articles’ information and summarized them in the standardized extraction form. Extracted data comprised: first author’s name, year of publication, study type, sample size, mean values and standard deviations of Ki-67 expression, lesion type (tumor/cyst), and the lesion name. Endnote X5 Resource Management Software was used to organize titles and abstracts of the articles and identify duplicates.

**Statistical analysis**

The Comprehensive Meta-Analysis (CMA; Englewood, NJ, USA) software, version 2.0, was used for data analysis. Mean and standard deviation values of ki-67 LI for each study were extracted from the selected articles. Q statistics and I\(^2\) were used to determine heterogeneity. A probability value of I\(^2\) value >50% and P value<0.10 for Cochran’s Q indicated significant heterogeneity. Based on heterogeneity analysis, fixed or random-effects models
were used. Subgroup analysis was performed based on the type of lesion, the lesion's name, and the sample size. Statistical significance was set at $P<0.05$.

**Results**

*Search results*

The initial search retrieved 1458 articles. Of 1458 papers, 859 studies remained to be assessed after the duplicates were removed. A total of 449 articles were excluded after reviewing the titles and abstracts, and the remaining 150 full-text articles were separately reviewed for quality by two investigators. Figure 1 presents the flowchart for the literature search and article selection procedures.

*Characteristics of studies*

At this stage, 132 studies were removed because the inclusion and exclusion criteria were not met. A few studies were excluded because of the method they used to report the immunohistochemical results. For example, in one study by Ramadoss et al., the mean score of Ki-67 was reported instead of Ki-67 LI or percentage. In the study by Otero et al., the mean ± SD was not reported separately for each lesion, and only a broad comparison was made. Also, in an article by Sathi et al., the results of immunohistochemical staining were not reported as mean ± SD, and therefore, it was removed from the study. Finally, 18 studies were included in this meta-analysis. Table 1 presents the descriptive characteristics and related data of the included studies.

*Publication bias*

An estimation of potential publication bias was carried out using the funnel plot. The asymmetry of the plot suggested publication bias (Figure 2). Egger linear regression test ($P<0.001$) showed statistically significant publication bias.

*Meta-analysis*

**Ki-67 expression in odontogenic tumors**

The 12 included studies reported Ki-67 LI for odontogenic tumors. The results revealed that the mean of Ki-67 expression in tumors was as follows: pooled mean=4.23, SD=0.38 ($P<0.001$). Considering the significant heterogeneity ($Q=743.03$, $df=28$, $P<0.001$, $I^2=96.23$), the random-effects model was used to calculate pooled LI mean at 95% CI (Figures 3 and 4). Subgroup analyses, based on the tumor type and the biopsies' volume are shown in Tables 2 and 3 and Figure 5, respectively.

![Figure 1. Search strategy and selection process of systematic review.](image-url)
Table 1. Descriptive characteristics and related data from included studies

| Authors            | Year | Country | Study type | Method | Type of lesion | No. of samples | Samples size | Ki-67 LI |
|--------------------|------|---------|------------|--------|----------------|----------------|--------------|---------|
| Ong’s et al       | 1997 | UK      | R          | IHC    | Ameloblastoma (folicular) | 24             | 5 µm            | 5.0     |
|                   |      |         |            |        | Ameloblastoma (plexiform) | 30             | 5 µm            | 3.2     |
| Sandra et al      | 2001 | Japan   | R          | IHC    | Ameloblastoma (solid)       | 15             | 4 µm            | 5.08    |
|                   |      |         |            |        | Ameloblastoma (mixed)       | 8              | 4 µm            | 4.2     |
|                   |      |         |            |        | Ameloblastoma (desmoplastic) | 3              | 4 µm            | 2.75    |
|                   |      |         |            |        | Ameloblastoma (plexiform)   | 9              | 4 µm            | 5.05    |
|                   |      |         |            |        | Ameloblastoma (folicular)   | 9              | 4 µm            | 3.70    |
|                   |      |         |            |        | Ameloblastoma (acanthomatous) | 3              | 4 µm            | 3.69    |
|                   |      |         |            |        | Unicystic ameloblastoma     | 5              | 4 µm            | 2.85    |
|                   |      |         |            |        | Unicystic ameloblastoma (cystic type ameloblastoma) | 9              | 4 µm            | 2.88    |
| Yoshida et al     | 2001 | Japan   | R          | IHC    | COC                  | 16             | 3 µm            | 2.68    |
|                   |      |         |            |        | Odontoma               | 7              | 3 µm            | 3.73    |
|                   |      |         |            |        | Radicular cyst          | 12             | 3 µm            | 2.96    |
| Piattelli et al   | 2002 | USA     | R          | IHC    | Dentigerous cyst        | 8              | 5 µm            | 3.14    |
|                   |      |         |            |        | Unicystic ameloblastoma   | 5              | 5 µm            | 5.32    |
| Yanamoto et al    | 2002 | Japan   | R          | IHC    | Ameloblastic carcinoma   | 2              | 3 µm            | 12.2    |
|                   |      |         |            |        | Ameloblastoma           | 10             | 3 µm            | 4.2     |
|                   |      |         |            |        | Ameloblastoma (folicular) | 7              | 3 µm            | 3.4     |
|                   |      |         |            |        | Ameloblastoma (plexiform) | 3              | 3 µm            | 5.9     |
| Fregnani et al    | 2003 | USA     | R          | IHC    | COC                  | 10             | 3 µm            | 1.3     |
| Suzuki T et al    | 2005 | Japan   | R          | IHC    | Radicular cyst          | 19             | 3 µm            | 1.59    |
| Tsuru et al       | 2008 | Japan   | R          | IHC    | OKC                  | 10             | 3 µm            | 15.4    |
|                   |      |         |            |        | Dentigerous cyst         | 10             | 3 µm            | 0.66    |
|                   |      |         |            |        | Radicular cyst           | 10             | 4 µm            | 1.4     |
| Razavi et al      | 2009 | Iran    | R          | IHC    | OKC                  | 16             | 4 µm            | 6.42    |
| Bello et al       | 2009 | Finland | R          | IHC    | Ameloblastoma           | 18             | 5 µm            | 6.4     |
|                   |      |         |            |        | Ameloblastic carcinoma   | 3              | 5 µm            | 18.2    |
| Razavi et al      | 2011 | Iran    | R          | IHC    | AOT                  | 16             | 4 µm            | 0.91    |
|                   |      |         |            |        | Ameloblastoma (solid type) | 16             | 4 µm            | 4.3     |
| Ayoub et al       | 2011 | Egypt   | R          | IHC    | OKC                  | 12             | 4 µm            | 2.68    |
|                   |      |         |            |        | Radicular cyst           | 13             | 4 µm            | 0.72    |
| Azevedo et al     | 2013 | Brazil  | R          | IFHC   | CECT                 | 19             | 5 µm            | 3.04    |
| Olimi et al       | 2014 | Romania | R          | IHC    | Ameloblastoma (folicular) | 15             | 4 µm            | 6.7     |
|                   |      |         |            |        | Ameloblastoma (acanthomatous) | 2              | 4 µm            | 4.1     |
|                   |      |         |            |        | Unicystic ameloblastoma (luminal) | 2          | 4 µm            | 6.2     |
|                   |      |         |            |        | Unicystic ameloblastoma (intraluminal) | 2          | 4 µm            | 5.6     |
| Özemur et al      | 2014 | Turkey  | R          | IHC    | Ameloblastoma           | 20             | 5 µm            | 1.58    |
|                   |      |         |            |        | Radicular cyst           | 20             | 5 µm            | 1.03    |
|                   |      |         |            |        | OKC                  | 20             | 5 µm            | 2.84    |
| Živković et al    | 2017 | Serbia  | R          | IHC    | OKC                  | 30             | 4 µm            | 0.190   |
|                   |      |         |            |        | Dentigerous cyst         | 30             | 4 µm            | 0.260   |
|                   |      |         |            |        | Radicular cyst           | 30             | 4 µm            | 0.270   |
| Apelláni et al    | 2018 | Uruguay | R          | IHC    | Ameloblastoma           | 10             | 5 µm            | 3.04    |
|                   |      |         |            |        | Unicystic ameloblastoma  | 10             | 5 µm            | 4.04    |
| Acharya et al     | 2018 | India   | R          | IHC    | OKC                  | 30             | 4 µm            | 7.55    |
|                   |      |         |            |        | Ameloblastoma           | 30             | 4 µm            | 8.19    |

Ki-67 LI: Ki-67 Labelling index; R: Retrospective; IHC: Immunohistochemistry; AOT: Adenomatoid Odontogenic Tumor; COC: Calcifying Odontogenic Cyst; OKC: Odontogenic Keratocyst.

**Ki-67 expression in odontogenic cysts**

Ten studies reported Ki-67 expression in odontogenic cysts.22,23,29,31,37 The results showed that the mean of Ki-67 expression for cysts was as follows: pooled mean = 1.04, SD = 0.07 (P < 0.001). Considering the significant heterogeneity (Q = 688.59, df = 16, P < 0.001, I² = 97.67), the random-effects model was used to calculate pooled LI mean at 95% CI (Figures 6 and 7). The results of subgroup analyses, based on the cyst type and the biopsies’ volume, are shown in Tables 4 and 5, and Figure 8, respectively.

**Discussion**

The present study was a systematic review to assess Ki-67 LI levels in odontogenic cysts and tumors. The issue’s significance was confirmed by the growth in the number of papers over the period searched. This study’s findings suggested increased Ki-67 LI levels in odontogenic tumors compared to cysts and in malignancies compared to benign lesions.

Although Ki-67 has increasingly been studied as a prognostic indicator in recent years, this marker’s more critical diagnostic role was emphasized in the present study. Simple histopathological techniques are not always able to differentiate between these challenging lesions. Random-effects model analysis was carried out for this purpose. Significantly higher Ki-67 LI levels were noted in ameloblastic carcinoma (17.59 ± 2.8%). The mean value obtained was significantly different from that in benign odontogenic lesions, consistent with previous studies. As observed by Yanamoto et al,24 the Ki-67 LI levels in
ameloblastic carcinoma (12.2 ± 12.2%) were higher than ameloblastoma (4.2 ± 3.6%). The findings of Bello et al provide additional support for the statistically significant difference in Ki-67 LI levels between ameloblastoma and ameloblastic carcinoma.

The same crucial diagnostic question has been explored in studies carried out on lesions in other anatomical areas, and the results are comparable to our findings. Faur et al reported higher Ki-67 expression in the malignant component of carcinoma tissue in pleomorphic adenoma than the benign component. The results were obtained from 29 cases of salivary gland tumors and the Ki-67 LI range for benign tumors was 0.5–6%, but the range was 3.6%–50% for malignant tumors. Therefore, the estimation of the potential proliferation rate of salivary gland tumors and identifying a subgroup of patients with invasive tumors, are useful in diagnostic pathology. This approach can differentiate between benign and malignant lesions and predict the prognosis of salivary gland tumors. In another study by Tadbir et al on Ki-67 expression in salivary gland tumors, the Ki-67 LI levels in malignant tumors (10.74 ± 10.89%) were higher than benign tumors, such as pleomorphic adenoma (0.78 ± 0.2%).

We also found that Ki-67 LI levels were higher in odontogenic tumors (pooled mean = 4.23 ±, SD = 0.38, P < 0.001) compared with odontogenic cysts (pooled mean = 1.04, SD = 0.07, P < 0.001). In a similar study, Piattelli et al found that Ki-67 expression in unicystic ameloblastoma was higher than in dentigerous cysts.

After ameloblastic carcinoma, the highest Ki-67 expression was seen in ameloblastoma (4.39 ± 0.47%), followed by unicystic ameloblastoma (4.12 ± 0.85%). A study by Olimid et al showed that unicystic ameloblastoma had the lowest proliferation activity compared to other types of ameloblastoma. The Ki-67 LI levels in odontogenic tumors were followed by CEOT (3.04 ± 1.75%), odontoma (2.96 ± 1.77%), and AOT (0.91 ± 1.71%) in descending order. Accordingly, the lowest Ki-67 expression among odontogenic tumors was seen in AOT. These results will be helpful in the pathologic diagnosis and differentiation of these tumors.

As shown in Table 3, there were significant correlations between Ki-67 LI expression and the biopsy volume in odontogenic tumors, except for the volume of 3 µm in odontogenic tumors. These findings might suggest that biopsy volumes of 4–5 µm would be more appropriate for assessing Ki-67 LI expression in odontogenic tumors.

Among odontogenic cysts, the highest Ki67-LI expression was seen in OKC (3.58 ± 0.51%), and the lowest
was observed in radicular cysts (0.98 ± 0.47%). These findings might be helpful in the histopathological analysis of cysts, especially when inflammation is present.

The order of Ki-67 LI expression in odontogenic cysts was as follows: OKC (3.58±0.51%), COC (2.43±0.65%), dentigerous cysts (1.29±0.62%), and radicular cysts (0.98 ± 0.47%) in descending order. These findings suggest that the assessment of Ki-67 LI in OKC during pathological diagnosis might be useful for diagnostic and therapeutic purposes. Tsuneki et al. reported that the expression level of Ki-67 in OKC was higher than that in dentigerous and radicular cysts. However, in contrast to our findings, Živković et al. found that Ki-67 expression in OKC was lower than both dentigerous and radicular cysts; this finding might be explained because the evaluation only concerned the suprabasal layer. On the other hand, in a study by Kuroyanagi et al., the expression level of Ki-67 was assessed in both the basal and suprabasal layers, and they observed higher Ki-67 expression in OKC compared with other odontogenic cysts. In another study by Pan et al., on OKC’s epithelial lining, Ki-67 immunopositive cells were found in both the basal and suprabasal layers.

In the present systematic review, covering 118 cases of OKC, 92 cases of radicular cysts, 33 cases of calcified odontogenic cysts (COC), and 48 cases of dentigerous cysts, we found the highest Ki-67 LI expression in OKC and the lowest expression in radicular cysts (Table 3). Therefore, it can be concluded that Ki-67 is expressed in developmental odontogenic cysts to a greater extent than inflammatory cysts, such as radicular cysts (0.98 ± 0.47%). Among developmental odontogenic cysts, the highest expression of Ki-67 was seen in OKC (3.58 ± 0.51%), with the lowest expression in dentigerous cysts (1.29 ± 0.62%). Selvi et al. reported higher Ki-67 expression in OKC compared with inflammatory and developmental cysts.

According to the data summarized in Table 2 (Ki-67

---

**Table 2.** Subgroup meta-analysis results of mean ki-67 expression for tumor type

| Tumor type                        | Number of studies | Point estimate | Standard error | Q-value | df (Q) | P value | \(I^2\) |
|-----------------------------------|-------------------|----------------|----------------|---------|--------|---------|---------|
| Ameloblastic carcinoma            | 2                 | 17.59          | 2.80           | 0.45    | 1      | 0.50    | 0.00    |
| Ameloblastoma                     | 9                 | 4.39           | 0.47           | 618.54  | 17     | 0.00    | 97.25   |
| AOT                               | 1                 | 0.91           | 1.71           | 0.00    | 0      | 1.00    | 0.00    |
| CEOT                              | 1                 | 3.04           | 1.75           | 0.00    | 0      | 1.00    | 0.00    |
| Odontoma                          | 1                 | 2.96           | 1.77           | 0.00    | 0      | 1.00    | 0.00    |
| Unicystic ameloblastoma           | 4                 | 4.12           | 0.85           | 16.98   | 5      | 0.00    | 70.56   |

AOT: Adenomatoid odontogenic tumor; CEOT: Calcifying epithelial odontogenic tumor.

**Table 3.** Subgroup meta-analysis results of the mean ki-67 expression for biopsy volume in tumors

| Biopsy volume | Number of studies | Point estimate | Standard error | Q-value | df (Q) | P value | \(I^2\) |
|---------------|-------------------|----------------|----------------|---------|--------|---------|---------|
| 3             | 2                 | 3.82           | 1.09           | 2.73    | 4      | 0.60    | 0.00    |
| 4             | 4                 | 4.19           | 0.54           | 123.80  | 14     | 0.00    | 88.69   |
| 5             | 6                 | 4.68           | 0.69           | 615.74  | 8      | 0.00    | 98.70   |
Figure 5. Forest plot diagram of mean Ki-67 expression for biopsy volume in odontogenic tumors.

Figure 6. Forest plot diagram of mean Ki-67 expression in odontogenic cysts (study identity).

Figure 7. Forest plot diagram of mean Ki-67 expression in odontogenic cysts (type of lesion).
LI expression in odontogenic tumors), when a cut-off point of 5% is set for Ki-67 LI levels, all the benign tumors drop below this point, while Ki-67 LI for ameloblastic carcinoma is much higher (17.5±2.8%). This fact plays an important diagnostic role and could suggest therapeutic approaches. In Table 4 (Ki-67 LI values in odontogenic cysts), it can be seen that in all odontogenic cysts, Ki-67 LI was less than 3%, except for OKC, which is regarded as a controversial lesion that, according to these findings, seems to be more similar to a tumor than a benign cyst. Although OKC is more commonly classified as an odontogenic cyst, it demonstrates features that distinguish it from other odontogenic cysts.

In the present study, the search strategy was limited to articles published in English. Articles that might contain data with potential high quality, written in other languages, were not included because of difficulties with accurate medical translation. In I^2 studies with statistical values that were <50%, we used the fixed-effects model and the Mantel-Hansel method, but in other studies where the values were >50% or the P-value was <0.05, the random-effects model was the most reliable option to calculate the overall effect size. The included studies’ heterogeneity might be caused by different methodological techniques, imperfect reporting of cases, absence of true case verification, or other uncertain reasons. Despite these limitations, we believe that crucial diagnostic information can be extracted from the meta-analysis since the results were based on the best available evidence.

**Conclusion**

In this systematic review, we found that when a cut-off point of 5% was set, ki-67 LI of all benign odontogenic tumors dropped below this point. All malignant tumors demonstrated an LI of >15.3%; a significantly higher Ki-67 LI in malignant odontogenic lesions (17.59±2.80) was observed. Among odontogenic tumors, the maximum and the minimum Ki-67 LIs were found in ameloblastoma (4.39±0.47) and AOT (0.91±1.71). Among odontogenic cysts, the highest Ki-67 LI was seen in OKC (3.58±0.51),
with the lowest for radicular cysts (1.29±0.62). Ki-67 LI in all odontogenic cysts was <3%, except for OKC. OKC might be more similar to a tumor, and a treatment plan similar to that for tumors might be suggested. Therefore, odontogenic lesions have diverse proliferative activities that help differentiate between various lesions and suggest therapeutic plans.

Authors’ Contributions
MJ: acquisition of data, drafting the work, revising the paper, and approving final draft. FPA: analysis and interpretation of data, drafting the work, revising the paper, and approving final draft. MVS: acquisition of data, revising the paper, and approving final draft. MK: concept and design of the work, interpretation of data, drafting the work, revising the paper, and approving final draft. MRH: interpretation of data for the work, drafting the paper, revising the paper, and approving final draft. NV: acquisition of data, revising the paper, and approving final draft.

Funding
This paper is based on a thesis submitted for DDS degree (NO. 62900) and was financially supported by the Research Council of Tabriz University of Medical Sciences (IR.TBZMED.VCR.REC.261). The research protocol was approved by the Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.VCR.REC.261). The authors declare no conflict(s) of interest related to the publication of this work.

Ethics Approval
The research protocol was approved by the Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.VCR.REC.1398.331).

Competing Interests
The authors declare no conflict(s) of interest related to the publication of this work.

References
1. Modi TG, Chalishazar M, Kumar M. Expression of Ki-67 in odontogenic cysts: a comparative study between odontogenic keratocysts, radicular cysts and dentigerous cysts. J Oral Maxillofac Pathol. 2018;22(1):146. doi: 10.4103/jomp. JOMFP.94.16.
2. Boifano P, Ruga E, Gallesio C. Keratocytic odontogenic tumor (odontogenic keratocyst): preliminary retrospective review of epidemiologic, clinical, and radiologic features of 261 lesions from University of Turin. J Oral Maxillofac Surg. 2010;68(12):2994-9. doi: 10.1016/j.oms.2010.05.068.
3. Wahba OM, Raghib AM, Megahed EM, Hussein MM. Expression of perlecan, syndecan-1 and Ki-67 in keratocystic odontogenic tumor. Tanta Dent J. 2013;10(3):153-9. doi: 10.1016/j.tjd.2013.12.003.
4. Soluk Tekkeşm M, Mutlu S, Olgaç V. Expressions of bax, Bcl-2 and Ki-67 in odontogenic keratocysts (Keratocytic Odontogenic Tumor) in comparison with ameloblastomas and radicular cysts. Turk Patojol Derg. 2012;28(1):49-55. doi: 10.5146/tipath.2012.01097.
5. Amaral FR, Mateus GC, Bonisson LA, de Andrade BA, Mesquita RA, Horta MC, et al. Cell proliferation and apoptosis in ameloblastomas and keratocystic odontogenic tumors. Braz Dent J. 2012;23(2):91-6. doi: 10.1590/s1013-64402012000200001.
6. Sah P, Menon A, Kamath A, Chandrashekar C, Carmelo S, Radhakrishnan R. Role of immunomarkers in the clinicopathological analysis of unicystic ameloblastoma. Dis Markers. 2013;35(5):481-8. doi: 10.1155/2013/517834.
7. Safadi RA, Quda BF, Hammad HM. Immunohistochemical expression of Ki-67, K8, K16, K17, K19, maspin, syndecan-1 (CD138), α-SMA, and Ki-67 in ameloblastoma and ameloblastic carcinoma: diagnostic and prognostic correlations. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(4):402-11. doi: 10.1016/j.oooo.2015.11.015.
8. Yoon HJ, Hong SP, Lee JI, Lee SS, Hong SD. Ameloblastic carcinoma: an analysis of 6 cases with review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(6):904-13. doi: 10.1016/j.tripleo.2009.06.045.
9. Alsaegh MA, Altaie AM, Zhu S. p63 expression and its relation to epithelial cells proliferation in dentigerous cyst, odontogenic keratocyst, and ameloblastoma. Pathol Onkol Res. 2020;26(2):1175-82. doi: 10.1111/t12253-019-00680-7.
10. de Paula AM, Carvalhais JN, Domingues MG, Barreto DC, Mesquita RA. Cell proliferation markers in the odontogenic keratocyst: effect of inflammation. J Oral Pathol Med. 2000;29(10):477-82. doi: 10.1034/j.1600-0714.2000.291001.x.
11. Alsaegh MA, Miyashita H, Zhu SR. Expression of human papillomavirus is correlated with Ki-67 and COX-2 expressions in keratocystic odontogenic tumor. Pathol Onkol Res. 2015;21(1):65-71. doi: 10.1016/j.j12253-014-9789-3.
12. Rahman F, Bhargava A, Tippur SR, Kaur M, Bhargava N, Kaur I, et al. Analysis of the immunopositivity of Ki-67 and Bcl-2 in the pericoronal tissues of impacted teeth, dentigerous cysts and gingiva using software image analysis. Dent Res J (Isfahan). 2013;10(1):31-7. doi: 10.4135/1733-3272.111764.
13. Ha SA, Shin SM, Namkoong H, Lee H, Cho GW, Hur SY, et al. Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res. 2004;10(24):8386-95. doi: 10.1158/0718-0432.ccr-04-1029.
14. Li LT, Jiang G, Chen Q, Zheng JN. Ki-67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11(3):1566-72. doi: 10.3892/mmr.2014.2914.
15. Beltran D, Faquin WC, Gallagher G, August M. Selective immunohistochemical comparison of polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma. J Oral Maxillofac Surg. 2006;64(3):415-23. doi: 10.1016/j.joms.2005.11.027.
16. Nagao T, Sugano I, Ishida Y, Hasegawa M, Matsuzaki O, Konno A, et al. Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and Bcl-2. Cancer. 1998;82(3):439-47.
17. Ramadoss R, Krishnan R, Peddanna S, Cherian E, Gunasekaran N, Thalayan D. Immunohistochemical analysis of cytokeratin 10, cytokeratin 14, epidermal growth factor receptor, tenasin, and Ki-67 in selected odontogenic cysts. SRM J Res Dent Sci. 2015;6(2):96-100. doi: 10.4103/0976-433x.135465.
18. Otero D, Lourenço SQ, Ruiz-Ávila I, Bravo M, Sousa T, de Faria PA, et al. Expression of proliferative markers in ameloblastomas and malignant odontogenic tumors. Oral Dis. 2013;19(4):360-5. doi: 10.1111/odi.12101.
19. Sathi GA, Tamamuru R, Tsujigawa H, Katase N, Leefluvar M, Sir CH, et al. Analysis of immunoeexpression of common cancer stem cell markers in ameloblastoma. Exp Ther Med. 2012;3(3):397-402. doi: 10.3892/etm.2011.437.
20. Ong’uti MN, Cruchley AT, Howells GL, Williams DM. Ki-67 antigen in ameloblastomas: correlation with clinical and histological parameters in 54 cases from Kenya. Int J Oral Maxillofac Surg. 1997;26(5):376-9. doi: 10.1016/s0901-5027(97)80801-6.
21. Sandra F, Mitsuyasu T, Nakamura S, Shiratsuchi Y, Ohishi M. Immunohistochemical evaluation of PCNA and Ki-67 in ameloblastoma. Oral Oncol. 2001;37(2):193-8. doi: 10.1016/s1368-8375(00)00079-8.
22. Yoshida M, Kumamoto H, Ooya K, Mayanagi H. Histopathological and immunohistochemical analysis of calcifying odontogenic cysts. J Oral Pathol Med. 2001;
30(10):582-8. doi: 10.1034/j.1600-0714.2001.301002.x.

23. Piattelli A, Lezzi G, Fioroni M, Santinelli A, Rubini C. Ki-67 expression in dentigerous cysts, unicystic ameloblastomas, and ameloblastomas arising from dental cysts. J Endod. 2002;28(2):55-8. doi: 10.1097/00004770-200202000-00001.

24. Yanamoto S, Kawasaki G, Mizuno A. Expression of p21WAF1/ CIP1, p53, and Ki-67 proteins in malignant ameloblastomas and ameloblastomas. Asian J Oral Maxillofac Surg. 2002;14(3):155-60. doi: 10.1016/s0915-6992(02)80037-1.

25. Bello IO, Alalen K, Slootweg PJ, Salo T. Alpha-smooth muscle actin within epithelial islands is predictive of ameloblastic carcinoma. Oral Oncol. 2009;45(9):760-5. doi: 10.1016/j.oraloncology.2008.11.011.

26. Razavi SM, Tabatabaie SH, Tavakoli Hoseini A, Tavakoli Hoseini E, Khabazian A. A comparative immunohistochemical study of Ki-67 and Bcl-2 expression in solid ameloblastoma and adenomatoid odontogenic tumor. Dent Res J (Isfahan). 2012;9(2):192-7. doi: 10.4103/1735-3327.95235.

27. Azevedo RS, Mosqueda-Taylor A, Carlos R, Cabral MG, Romañach MJ, de Almeida OP, et al. Calculifying epithelial odontogenic tumor (CEOT): a clinicopathologic and immunohistochemical study and comparison with dental follicles containing CEOT-like areas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(6):759-68. doi: 10.1016/j.ooos.2013.08.023.

28. Olimid DA, Florescu AM, Cernea D, Georgescu CC, Mărgăritescu C, Simionescu CE, et al. The evaluation of p16 and Ki-67 immunoexpression in ameloblastomas. Rom J Morphol Embryol. 2014;55(2):363-7.

29. Özçamur-Güneş Ç, Olgaç V, Soluk-Tekkesin M, Gürkan-Koşeoğlu B. Ki-67 and cyclooxygenase-2 expression in odontogenic keratocysts: a clinicopathologic and immunohistochemical study. Int J Med Sci. 2012;9(4):262-8. doi: 10.7150/ijms.4243.

30. Apellániz D, Pereira-Prado V, Sicco E, Vigil-Bastitga G, González-González R, Mosqueda-Taylor A, et al. Comparative Study of the Minichromosome Maintenance Proteins Complex (MCM 4/5/6) in Ameloblastoma and Unicystic Ameloblastoma. Int J Surg Pathol. 2018;26(8):714-20. doi: 10.1177/1066896918778341.

31. Acharya S, Arnold D, Prabhu P, Niranjani KC, Hallikeri K. MCM-2 an alternative to Ki-67 for assessing cell proliferation in odontogenic pathologies. J Oral Maxillofac Surg Med Pathol. 2019;31(1):52-8.

32. Fregnani ER, Pires FR, Quezada RD, Shih le M, Vargas PA, de Almeida OP. Calculifying odontogenic cyst: clinicopathological features and immunohistochemical profile of 10 cases. J Oral Pathol Med. 2003;32(3):163-70. doi: 10.1034/j.1600-0714.2003.00070.x.

33. Suzuki T, Kumamoto H, Kunimori K, Ooya K. Immunohistochemical analysis of apoptosis-related factors in lining epithelium of radicular cysts. J Oral Pathol Med. 2005;34(1):46-52. doi: 10.1111/j.1600-0714.2004.00248.x.

34. Tsuneki M, Cheng J, Maruyama S, Ida-Yonemochi H, Nakajima M, Saku T. Perlecan-rich epithelial linings as a background of proliferative potentials of keratocystic odontogenic tumor. J Oral Pathol Med. 2008;37(5):287-93. doi: 10.1111/j.1600-0714.2007.00620.x.

35. Razavi SM, Ardakani SH. A comparison of antigens Bcl-2 and Ki-67 expression alongside apoptosis between odontogenic keratocysts and ameloblastomas. J Isfahan Dent Sch. 2009;5(3):139-48.

36. Ayoub MS, Baghdadi HM, El-Kholy M. Immunohistochemical detection of laminin-1 and Ki-67 in radicular cysts and keratocytic odontogenic tumor. BMC Clin Pathol. 2011;11:4. doi: 10.1186/1472-6890-11-4.

37. Živković ND, Mihailović DS, Kostić MS, Cvetanović AS, Mijović Ž, Miletijević MV, et al. Markers of proliferation and cytokeratins in the differential diagnosis of jaw cysts. Ear Nose Throat J. 2017;96(9):376-83.

38. Faur AC, Sas I, Motoc AG, Cornianu M, Zamfir CL, Lazar DC, et al. Ki-67 and p53 immunostaining assessment of proliferative activity in salivary tumors. Rom J Morphol Embryol. 2013;56(4):1299-309.

39. Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri A, et al. Expression of Ki-67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev. 2012;13(10):5155-9. doi: 10.7314/apjcp.2012.13.10.5155.

40. Kuroyanagi N, Sakuma H, Miyabe S, Machida J, Kaetsu A, Yokoi M, et al. Prognostic factors for keratocystic odontogenic tumor (odontogenic keratocyst): analysis of clinicopathologic and immunohistochemical findings in cysts treated by enucleation. J Oral Pathol Med. 2009;38(4):386-92. doi: 10.1111/j.1600-0714.2008.00729.x.

41. Pan S, Li Tj, PTCH1 mutations in odontogenic keratocysts: are they related to epithelial cell proliferation? Oral Oncol. 2009;45(10):861-5. doi: 10.1016/j.oraloncology.2009.02.003.

42. Selvi F, Tekkesin MS, Cakarer S, Isler SC, Keskin C. Keratocystic odontogenic tumors: predictive factors of recurrence by Ki-67 and AgNOR labelling. Int J Med Sci. 2012;9(4):262-8. doi: 10.7150/ijms.4243.